2 Information about brodalumab

Information about brodalumab

Marketing authorisation

Brodalumab (Kyntheum, Leo Pharma) is indicated for the treatment of 'moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'.

Dosage in the marketing authorisation

The recommended dose is 210 mg administered by subcutaneous injection at weeks 0, 1 and 2, followed by 210 mg every 2 weeks.


£1,280 per pack of 2 syringes of 210 mg/1.5 ml solution (excluding VAT; British national formulary [BNF] online [accessed January 2018]).

The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of brodalumab, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.

  • National Institute for Health and Care Excellence (NICE)